Research is being conducted to understand the relationship between weight-loss drugs, such as GLP-1s, and cancer risk. Some studies suggest that these drugs may have a protective effect against cancer, while others indicate they may have little to no impact on the risk of obesity-related cancers. The scientific community appears to be undecided on the issue, with some outlets reporting potential benefits and others highlighting potential complications or limited effects.